Ad
related to: aerotek pharmaceutical solutions llc address headquarters zip code
Search results
Results From The WOW.Com Content Network
Founded as Aerotek in 1983 by Jim C. Davis and Steve Bisciotti, the company originally focused on the engineering and aerospace industry. [3] Bisciotti would go on to become owner of the Baltimore Ravens. [1] [4] As of January 2023, Jay Alvather serves as the Allegis Group CEO. [5] Allegis Group's subsidiaries include: [1] Aerotek
This page was last edited on 23 January 2025, at 00:20 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
As of 2019, twelve of top 20 biopharmaceutical companies in the world has U.S. headquarters in the state. [ 9 ] [ 10 ] Below is a list of notable New York metropolitan area biotechnology and pharmaceutical corporations , including companies with either global or U.S. headquarters in the metropolitan region encompassing and surrounding New York ...
Baxter sold its BioPharma Solutions business in October for $4.25 billion to investment firms. The new company, Simtra, wants to expand.
Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets ...
In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion, [7] which would return Allergan to the U.S. for tax purposes. [8] On the announcement of the transaction, Abbvie disclosed that its 2019 net effective tax rate was 9%, but that post the acquisition, the Group's effective ...
In 2008, Medsn officially became Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States. [7] [12] In 2009, Indegene signed a master service agreement with six pharmaceutical companies.
In 2014, Pernix became one of the fastest growing specialty pharmaceutical companies in the US, with an expanding CNS franchise and opportunities to branch out into adjacent therapeutic areas. Additionally, in 2014, the company completed several acquisitions including the acquisition of TREXIMET from GSK and KHEDEZLA from Osmotica.